Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy

Lancet

Volumn 356, Issue 9231, 2000, Pages 713-718

  Shapiro, E ^a   Krivit, W ^a   Lockman, L ^a   Jambaque I ^b   Peters, C ^a   Cowan, M ^c   Harris, R ^d   Blanche, S ^g   Bordigoni, P ^e   Loes, D ^a   Ziegler, R ^a   Crittenden, M ^c   Ris, D ^d   Berg, B ^c   Cox, C ^f   Moser, H ^f   Fischer, A ^g   Aubourg, P ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e CHU NANCY BRABOIS   (France)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADRENOLEUKODYSTROPHY; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; DEMYELINATION; FOLLOW UP; HUMAN; INTELLIGENCE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; TREATMENT OUTCOME; X CHROMOSOME LINKAGE;

EID: 0034718378     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02629-5     Document Type: Article

References (34)

1. Therapy of X-linked adrenoleukodystrophy: Prognosis based upon age and MRI abnormality and plans for placebo-controlled trials
2. The incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes
3. Adrenoleukodystrophy: Failure of immunosuppression to prevent neurological progression
4. Childhood adrenoleukodystrophy: Failure of intensive immunosuppression to arrest neurologic progression
5. Progression of X-linked adrenoleukodystrophy under interferon-beta therapy
6. Dietary erucic acid therapy for X-linked adrenoleukodystrophy
7. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy
8. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy
9. Reversal of early neurological and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation
10. Bone marrow transplant in adrenoleukodystrophy
11. Childhood onset of cerebral adrenoleukodystrophy: Effective treatment by bone marrow transplantation
12. Childhood cerebral form of adrenoleukodystrophy: Short-term effect of bone marrow transplantation on brain MR observations
13. Adrenoleukodystrophy: A scoring method for brain MR observations
14. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation
15. Measurement of saturated very long chain fatty acids in plasma
16. Capillary-gas liquid chromatographic mass spectrometric measurement of very long chain (C22 to C26) fatty acids in microliter samples of plasma
17. A two-year trial of oleic and erucic acids (Lorenzo's oil) as treatment for adrenomyeloneuropathy
18. X-linked adrenoleukodystrophy
19. The worldwide hematopoietic cell transplantation experience for cerebral X-adrenoleukodystrophy
20. Effective treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation
21. X-linked adrenoleukodystrophy: Genes, mutations, and phenotypes
22. Mutations in the gene for X-linked adrenoleukodystrophy in patients with different clinical phenotypes
23. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
24. Identification of mutations in the putative ATP-binding domain of the adrenoleukodystrophy gene
25. Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy
26. Missense mutations are frequent in the gene for X-chromosomal adrenoleukodystrophy (ALD)
27. Mutational analysis of patients with X-linked adrenoleukodystrophy
28. Spectrum of mutations in the gene encoding the adrenoleukodystriophy protein
29. Plasma very long chain fatty acids in 3,000 peroxisome disease patients anti 29,000 controls
30. Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells
31. Lovastatin for X-linked adrenoleukodystrophy
32. Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy